Базальная инсулинотерапия у пациентов с сахарным диабетом 2-го типа: аспекты раннего назначения, преимущества, ограничения, перспективы

Интенсивный контроль гликемии непосредственно с дебюта сахарного диабета 2-го типа (СД2) имеет приоритетное значение для снижения риска и долгосрочного прогноза сердечно-сосудистых осложнений. Стратегия ранней интенсификации терапии СД2 с помощью инсулина до настоящего времени остается предметом острых дискуссий. Выбор оптимального режима для старта инсулинотерапии также не имеет однозначного решения. Гипогликемии являются основным фактором, традиционно ограничивающим более широкое применение инсулинотерапии у пациентов с СД2. Выбор в пользу базальной инсулинотерапии аналогами инсулина имеет преимущества в достижении целевых показателей углеводного обмена при значимо меньшем риске гипогликемий по сравнению с другими режимами инсулинотерапии.

сахарный диабет 2-го типа, сердечно-сосудистый риск, инсулинотерапия, инсулин гларгин

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:14:977-986.

2. Nathan D.M., Cleary P.A., Backlund J.Y. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:25:2643-2653.

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

4. Holman R.R., Paul S.K., Bethel M.A. et al. 10-year follow-up of intensive glucose control in type 2 diabetes mellitus. N Engl J Med 2008;359:1577-1589.

5. Patel A., MacMahon S., Chalmers J. et al. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.

6. Gerstein H.C., Miller M.E., Byington R.P. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.

7. Duckworth W., Abraira C., Mortiz T. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.

8. Turner R.C., Cull C.A., Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: prospective requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.

9. Weng J., Li Y., Xu W. et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008;371:1753-1760.

10. Home P.D., Boulton A.J., Jimenez J. et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 2003;20:2:63-71.

11. Wright A., Burden A.C., Paisey R.B. et al. Efficacy of addition of insulin over 6 yers in patients with type 2 diabetes in the U. K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:2:330-336.

12. Monnier L., Lapinski H., Colette C. Contributions of Fasting and Postprandial Plasma Glucose increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients. Diabetes Care 2003;26:881-885.

13. Riddle M., Umpierrez G., Digenio A. et al. Challenging the «Monnier Concept»: High Basal (not Postprandial) Glucose Dominates Hyperglycemic Exposure over a Wide Range of A1C on Oral Therapy, and Contributes Significantly Even after Addition of Basal Insulin. Am Diabet Ass 2010;Abstract:626.

14. Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the study of diabetes. Diabetes Care 2008;31:1-11.

15. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31:Suppl 1:S12-S54.

16. Guideline for management of postmeal glucose. International Diabetes Federation, 2007. [Available at: http://www.idf.org]

17. Алгоритмы специализированной помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. М 2009.

18. Mäkimattila S., Nikkilä K., Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:4:406-412.

19. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:6:1389-1394.

20. Sarwar N., Gao P. et al. Emerging Risk Factors Collaboration, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222.

21. Skyler J.S., Bergenstal R., Bonow R.O. et al. Intensive glycemic control nd the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Tials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357.

22. Yki-Jarvinen H. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.

23. Riddle M. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.

24. Rosenstock J., Dailey G., Massi-Benedetti M. et al. Reduced hypoglycemia risk with insulin glargine: a metaanalysis comparing insulin glargine with human NPH in type 2 diabetes. Diabetes Care 2005;28:950-955.

25. Mullins P., Sharplin P., Yki-Jarvinen H. et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin Glargine compared with Neutral Protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:8:1607-1619.

26. Gerstein H.C., Yale J.F., Harris S.B. et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:7:736-742.

27. Bretzel R.G., Nuber U., Landgraf W. et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084.

28. Залевская А.Г., Вербовая Н.И., Родионова Т.И. и др. Базальная инсулинотерапия у пациентов с сахарным диабетом типа 2 с неудовлетворительным контролем гликемии на пероральной сахарснижающей терапии: результаты прямого сравнительного исследования аналогов инсулина Лантус и Левемир. Сахарный диабет 2010;2:47:106-112.

29. Schreiber S.A., Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9:1:31-38.

30. The ORIGIN Trial Investigators Hamilton, Ontario, Canada Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:1:26-32.

31. The DECODE Study group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.